Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.35 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | NOS2 | P35228 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL551505 | 0.98 | NOS3 (0.34) | NOS3NOS1NOS2ALDH1A1MEN1 | |
| SCHEMBL4655276 | 0.98 | NOS3 (0.37) | NOS3NOS1NOS2ALDH1A1KDM4E | |
| SCHEMBL18240335 | 0.95 | NOS3 (0.35) | NOS3NOS1NOS2ALDH1A1KDM4E | |
| SCHEMBL18274776 | 0.95 | NOS3 (0.35) | NOS3NOS1NOS2ALDH1A1KDM4E | |
| SCHEMBL10413624 | 0.95 | NOS3 (0.35) | NOS3NOS1NOS2ALDH1A1KDM4E | |
| SCHEMBL7761924 | 0.95 | NOS3 (0.35) | NOS3NOS1NOS2ALDH1A1KDM4E | |
| SCHEMBL11231757 | 0.95 | NOS3 (0.35) | NOS3NOS1NOS2ALDH1A1KDM4E | |
| SCHEMBL8529809 | 0.95 | NOS3 (0.35) | NOS3NOS1NOS2ALDH1A1KDM4E | |
| SCHEMBL5271505 | 0.95 | NOS3 (0.35) | NOS3NOS1NOS2ALDH1A1KDM4E | |
| SCHEMBL6079563 | 0.93 | NOS3 (0.32) | NOS3NOS1NOS2KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668179-B1 | NEW 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INT (DE) | 2017-08-16 | — | — | EP | claimed |
| EP-2668178-B1 | NEW 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INT (DE) | 2016-01-20 | — | — | EP | claimed |
| WO-2023218484-A1 | BICYCLIC COMPOUNDS AND THEIR USE AS PEST CONTROL AGENTS | PI INDUSTRIES LTD. (IN) | 2023-11-16 | — | — | WO | disclosed |
| EP-2668179-B1 | NEW 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INT (DE) | 2017-08-16 | — | — | EP | disclosed |
| EP-1829874-B1 | TRICYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2014-02-12 | — | — | EP | disclosed |
| WO-2007017179-A1 | USE OF IONIC UV-A SUNSCREENS | DSM IP ASSETS B.V. (NL) | 2007-02-15 | — | — | WO | disclosed |
| EP-1599465-A1 | SUBSTITUTED N-ARYL NITROGEN HETEROCYCLES | Bayer CropScience AG (DE) | 2005-11-30 | — | — | EP | disclosed |
| US-20040242876-A1 | Process for the preparation of (pyrimmidin-2-yl) methyl ketones | LONZA LTD. (CH) | 2004-12-02 | — | — | US | disclosed |
| WO-2004074274-A1 | SUBSTITUTED N-ARYL NITROGEN HETEROCYCLES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2004-09-02 | — | — | WO | disclosed |
| US-6780992-B2 | 5-(4-(2-(2,4-DIMETHYL-6-OXO-1,6-DIHYDRO-1-PYRIMIDINYL) -ETHOXY)PHENYL METHYL)THIAZOLIDINE-2,4-DIONE FOR EXAMPLE; ALSO OXAZOLIDINE-2,4-DIONE, AND 1,2,4-OXADIAZOLIDINE-3,5-DIONE DERIVATIVES; REDUCING BLOOD GLUCOSE LEVELS | DR. REDDY'S LABORATORIES LTD. (IN) | 2004-08-24 | — | — | US | disclosed |
| US-20020123502-A1 | Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases | DR. REDDY'S RESEARCH FOUNDATION & REDDY-CHEMINOR, INC. | 2002-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020123502-A1 | Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases | IAPP, GPR119, CYP11B1 | NOS3 1395/4885NOS1 1080/4885NOS2 1228/4885 |
| US-20040242876-A1 | Process for the preparation of (pyrimmidin-2-yl) methyl ketones | MRM1, CYP2E1, CBR1 | NOS3 1041/4885NOS1 817/4885NOS2 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.